What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer? Journal Article


Authors: Kollmeier, M. A.; Zelefsky, M. J.
Article Title: What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Abstract: This Practice Point commentary discusses the paper by Horwitz and colleagues, which reported the long-term results of the RTOG 92-02 trial in which patients with locally advanced, node-negative prostate cancer who were treated with neoadjuvant-concurrent hormone ablation therapy and external beam radiation therapy (70 Gy) were subsequently randomized to receive either no further androgen deprivation or long-term (2-year) goserelin therapy. The results at 10 years confirm biochemical and clinical outcome benefits with the use of long-term androgen deprivation therapy for patients treated with conventional-dose radiotherapy. How these results should best be incorporated into dose-escalated radiotherapeutic approaches remains unclear, however, and this issue requires further investigation.
Keywords: cancer survival; overall survival; androgen; clinical trial; advanced cancer; cancer growth; cancer radiotherapy; disease free survival; radiation dose; distant metastasis; prostate cancer; prostatic neoplasms; goserelin; gastrointestinal toxicity; radiation dose fractionation; androgen antagonists; long term care; brachytherapy; short survey; external beam radiotherapy; antineoplastic agents, hormonal; androgen therapy; androgens
Journal Title: Nature Clinical Practice Urology
Volume: 5
Issue: 11
ISSN: 1743-4270
Publisher: Nature Publishing Group  
Date Published: 2008-01-01
Start Page: 584
End Page: 585
Language: English
DOI: 10.1038/ncpuro1217
PUBMED: 18813218
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 17 November 2011" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael J Zelefsky
    754 Zelefsky
  2. Marisa A Kollmeier
    227 Kollmeier